Supported by an educational grant from Sun Pharmaceutical Industries Ltd
Epilepsy affects about 4.3 million adults in the United States. For patients with epilepsy, the goal of treatment is to achieve seizure freedom with minimal or no adverse events. At this time, more than one-third of patients who experience seizures continue to have them despite diagnosis and treatment. Patients who experience refractory seizures have higher morbidity and mortality along with poorer quality of life compared with those who achieve adequate seizure control. The development of new antiepileptic drugs (AEDs) over the last decade has been prompted by the fact that available AEDs did not provide optimal care in managing epilepsy. Many patients failed all available options because their seizures were not adequately controlled, they were experiencing severe side effects, or nonadherence was a factor. Because treatment options have increased, drug therapy can now be tailored to the requirements of individual patients.
Neurologists and primary care clincians (eg, internists, family physicians/general practitioners, nurse practitioners, and physician assistants) engaged in the management and care of patients with epilepsy.
Upon completion of this activity, participants should be better able to:
Identify patients diagnosed with partial-onset seizures who may be suboptimally treated or experiencing drug-resistant/refractory epilepsy
Differentiate the safety, efficacy, mechanisms of action, and drug technologies among newer antiepileptic drugs (AEDs)
Develop a therapeutic regimen that achieves the goal of therapy: eliminating seizures while minimizing adverse effects, which may include utilizing drug-sparing strategies and monotherapy
Formulate care plans with a patient‐centric approach and more effective patient-caregiver communication in regard to treatment options, pill burden, adherence, improving outcomes, and quality of life
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Joseph I. Sirven, MD Professor of Neurology and Chairman Department of Neurology Mayo Clinic Scottsdale, AZ
Dr. Sirven has received consulting fees from Acorda Therapeutics, Inc; Upsher-Smith Laboratories, Inc; UCB, Inc; and NeuroPace, Inc.
Sheryl Haut, MD Director, Adult Epilepsy Program Montefiore Medical Center Albert Einstein College of Medicine Bronx, NY
Dr. Haut has received consulting fees from Acorda Therapeutics, Inc, and Siga Technologies, Inc, and research grants from GW Pharmaceuticals.
Faculty Reviewer Marcello Morgan, MD, MPH, CHCP Associate Medical Director Haymarket Medical Education Paramus, NJ
Dr. Morgan has nothing to disclose with regard to commercial support.
Publishing Staff Disclosures
Priya Wanchoo, MD, Java Solis, and Lori Marrese of Haymarket Medical Education have nothing to disclose with regard to commercial support.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Sun Pharmaceutical Industries Ltd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.